港股创新药再迎反弹

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a rebound, with multiple innovative drug ETFs rising over 3%, indicating renewed market interest after a prolonged adjustment period [3][4]. Market Performance - On March 16, the Hong Kong market saw a collective rise in major indices, with the Hang Seng Index, Hang Seng Tech Index, and Hang Seng China Enterprises Index increasing by 1.45%, 2.69%, and 1.67% respectively [5]. - The Hang Seng Innovative Drug Index led the gains with a 3.18% increase, while 18 cross-border ETFs related to "innovative drugs" and "pharmaceuticals" collectively rose over 2%, averaging a 2.67% increase [5][6]. - Trading activity was robust, with the total trading volume of the mentioned ETFs exceeding 12.5 billion yuan, a 45% increase from the previous trading day [6]. Fund Flows - Since the fourth quarter of last year, approximately 22 billion yuan has flowed into innovative drug ETFs, with 4.93 billion yuan entering in 2023 alone [6][7]. - Notable inflows were seen in the Huatai-PB Hang Seng Innovative Drug ETF and the GF Hang Seng Innovative Drug ETF, which attracted 2.105 billion yuan and 1.578 billion yuan respectively [7]. Sector Analysis - The innovative drug sector has faced a significant adjustment, with the Hang Seng Innovative Drug Index dropping over 21.5% since the fourth quarter of last year [8]. - The recent adjustments are viewed as a normal market correction rather than a deterioration of the industry's fundamentals, with the sector's valuation returning to a reasonable range [8][9]. - The potential for profitable companies to emerge is highlighted, as many firms are expected to reach profitability between 2026 and 2028, which could lead to significant alpha generation [9]. Investment Outlook - The market is anticipated to shift from broad valuation reassessment to a focus on fundamental performance, with only companies demonstrating profitability and core competitiveness likely to thrive [9][10]. - Concerns remain regarding the impact of AI technology on the pharmaceutical industry, prompting some fund managers to adopt a cautious stance [9][10]. External Factors - Southbound capital has been a significant support for the Hong Kong market, with a cumulative net inflow exceeding 180 billion yuan in 2023 [10][11]. - The overall market dynamics are influenced by external liquidity conditions and the U.S. interest rate environment, which could affect the pace of valuation recovery [11][12]. - The rebound in the Hong Kong market is expected to be driven by corporate earnings realization, sustained southbound capital inflows, and marginal improvements in the domestic macroeconomic environment [12].